Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Australian Journal of Chemistry Australian Journal of Chemistry Society
An international journal for chemical science
RESEARCH ARTICLE

Parallel Solution-Phase Synthesis of Targeted Tyrphostin Libraries with Anticancer Activity

Timothy A. Hill A , Jennette A. Sakoff B , Phillip J. Robinson C and Adam McCluskey A D
+ Author Affiliations
- Author Affiliations

A Chemistry, School of Environmental and Life Sciences, University of Newcastle, Callaghan NSW 2308, Australia.

B Department of Medical Oncology, Mater Misericordiae Hospital, Waratah NSW 2298, Australia.

C Children’s Medical Research Institute, 214 Hawkesbury Road, Westmead NSW 2145, Australia.

D Corresponding author. Email: Adam.McCluskey@newcastle.edu.au

Australian Journal of Chemistry 58(2) 94-103 https://doi.org/10.1071/CH04143
Submitted: 3 June 2004  Accepted: 25 October 2004   Published: 21 February 2005

Abstract

The combination of semi-automation, an elegant synthesis, and parallel solution-phase synthesis approaches has allowed the development of five targeted, symmetrical tyrphostin compound libraries. These libraries on average are comprised of 12 compounds. Notwithstanding this, low micromolar potent growth inhibitors against HT29 (colorectal carcinoma) and G401 (renal carcinoma) cell lines were discovered. Additionally, significant SAR data was obtained. We noted that the most potent growth inhibitory activity was consistently observed for those analogues that possessed a 2-chlorophenyl (for 10: GI50 HT29 5.5 ± 0.4 μM, GI50 G401 2.6 ± 0.4 μM; for 23: GI50 HT29 2.4 ± 0.2 μM, GI50 G401 1.9 ± 1 μM; for 34: GI50 HT29 8.8 ± 3.1 μM, GI50 G401 6.2 ± 2.9 μM; for 46: GI50 HT29 5.2 ± 0.9 μM, GI50 G401 3.7 ± 0.6 μM; for 57: GI50 HT29 4.6 ± 0.8 μM, GI50 G401 2.1 ± 0.2 μM), a 3-chlorophenyl (for 11: GI50 HT29 3.8 ± 0.7 μM, GI50 G401 1.7 ± 0.7 μM; for 48: GI50 HT29 5.9 ± 0.1 μM, GI50 G401 3.4 ± 0.6 μM; for 58: GI50 HT29 4.8 ± 0.9 μM, GI50 G401 3.4 ± 0.2 μM), or a 3-methoxyphenyl substituent (for 13: GI50 HT29 7.4 ± 3.8 μM, GI50 G401 2.8 ± 0.5 μM; for 26: GI50 HT29 4.5 ± 0.5 μM, GI50 G401 4.9 ± 1 μM; for 37: GI50 HT29 3.7 ± 0.2 μM, GI50 G401 1.6 ± 0.2 μM; for 49: GI50 HT29 3.7 ± 0.4 μM, GI50 G401 3.4 ± 0.2 μM; for 60: GI50 HT29 4.1 ± 0.6 μM, GI50 G401 1.8 ± 0.3 μM). Finally, we noted that increasing the distance between the terminal aromatic rings had only a minimal effect on the 2-, 3-chlorophenyl, and 3-methoxyphenyl analogues, but did have a favourable effect on OH, COOH, and multiply substituted analogues.


Acknowledgments

We acknowledge financial support from the University of Newcastle and the NHMRC, Australia.


References


[1]   U.S. Food and Drug Administration: Approved New Molecules for Cancer Use per Year.
       www.accessdata.fda.gov/scripts/cder/onctools/statistics.cfm

[2]   E. Chu, M. R. Grever, B. A. Chabner, Cancer Drug Development in Cancer: Principles and Practice of Oncology, 6th edn 2001, p. 335 (Lippincott Williams & Wilkins: Philadelphia, PA).

[3]   A. Gazit, P. Yaish, C. Gilon, A. Levitski, J. Med. Chem. 1989, 32,  2344.
         
         
        | Crossref |  GoogleScholarGoogle Scholar |  
        | Crossref |  GoogleScholarGoogle Scholar |  
         
        | Crossref |  GoogleScholarGoogle Scholar |  
         
         
        | Crossref |  GoogleScholarGoogle Scholar |  
        | Crossref |  GoogleScholarGoogle Scholar |  
        | Crossref |  GoogleScholarGoogle Scholar |  open url image1